| 47.51 -0.52 (-1.08%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 63.94  |
1-year : | 69.97 |
| Resists | First : | 54.74 |
Second : | 59.9 |
| Pivot price | 54.34 |
|||
| Supports | First : | 46.4 |
Second : | 38.6 |
| MAs | MA(5) : | 50.13 |
MA(20) : | 55.01 |
| MA(100) : | 60.89 |
MA(250) : | 59.67 |
|
| MACD | MACD : | -2.8 |
Signal : | -2.2 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 12 |
| RSI | RSI(14): 28.9 |
|||
| 52-week | High : | 94.75 | Low : | 19.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APLS ] has closed above bottom band by 0.5%. Bollinger Bands are 9.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.92 - 49.2 | 49.2 - 49.5 |
| Low: | 45.64 - 45.94 | 45.94 - 46.27 |
| Close: | 46.94 - 47.47 | 47.47 - 48.04 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Thu, 18 Apr 2024
Insiders Could Have Profited By Holding onto Apellis Pharmaceuticals Shares Despite 15% Drop - Simply Wall St
Thu, 18 Apr 2024
FY2025 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Reduced by Analyst - MarketBeat
Mon, 15 Apr 2024
Expert Ratings For Apellis Pharmaceuticals - Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga
Thu, 28 Mar 2024
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Wed, 28 Feb 2024
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 27 Feb 2024
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 121 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 13.2 (%) |
| Held by Institutions | 95.9 (%) |
| Shares Short | 10,440 (K) |
| Shares Short P.Month | 10,060 (K) |
| EPS | -4.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | -133.3 % |
| Operating Margin | -57.8 % |
| Return on Assets (ttm) | -41.8 % |
| Return on Equity (ttm) | -290.2 % |
| Qtrly Rev. Growth | 545.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.28 |
| EBITDA (p.s.) | -4.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -595 (M) |
| Levered Free Cash Flow | -405 (M) |
| PE Ratio | -10.68 |
| PEG Ratio | -1.4 |
| Price to Book value | 29.14 |
| Price to Sales | 14.44 |
| Price to Cash Flow | -9.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|